… Consequently, therapeutic strategies targeting ER stress-related interventions have attracted
… ER stress in cancer, metabolic, and neurodegenerative diseases, offering novel therapeutic …

… , demanding novel treatment strategies such as immune checkpoint inhibition in tumors with
… of 10) but highly infrequent in neuroendocrine neoplasms from many other sites. The lack of …

… vasculature and tumor immunity, which play different roles in cancer progression. DLLs … as
anti-cancer therapeutics. In this review, we discuss the role of DLLs in cancer and summarize …

… Grading and correct histological diagnosis are important regarding pNEN treatment strategy.
Grading based on the Ki-67 index has been proven to be the most reliable factor in the …

… gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) can be divided into well
differentiated neuroendocrine tumors G3 (NETs G3) and poorly differentiated neuroendocrine …

… novel therapeutic strategies, including targeted therapies … evolvement of novel technologies
and molecular markers. Aubert … and everolimus for pancreatic neuroendocrine tumors, and …

… cancer is a heterogeneous disease that is driven by genetic, … article we review genetic and
non-genetic causes of tumor … heterogeneity has on resistance to therapy. We will provide …

… of citrate in the regulation of both tumor cells and immune cells, the underlying molecular
mechanisms, and the potential of using citrate as a novel therapeutic agent and a biomarker. …

… therapies, active research avenues explore the development of novel therapeutics that target
the crosstalk between cancer and … In this review, we discuss the therapeutic opportunities …

… 177 lutetium-DOTATATE will target the tumor cells by emitting β and γ radiations, forming
the basis for the novel treatment known as peptide receptor radionuclide therapy or PRRT[78]. …